SANGAMO THERAPEUTICS INC's ticker is SGMO and the CUSIP is 800677106. A total of 197 filers reported holding SANGAMO THERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is 0.77 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $600 | -53.8% | 1,000 | 0.0% | 0.00% | -100.0% |
| Q2 2023 | $1,300 | -26.1% | 1,000 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $1,760 | -43.9% | 1,000 | 0.0% | 0.00% | -50.0% |
| Q4 2022 | $3,140 | -37.2% | 1,000 | 0.0% | 0.00% | -50.0% |
| Q3 2022 | $5,000 | +25.0% | 1,000 | 0.0% | 0.00% | +33.3% |
| Q2 2022 | $4,000 | -33.3% | 1,000 | 0.0% | 0.00% | -25.0% |
| Q1 2022 | $6,000 | -25.0% | 1,000 | 0.0% | 0.00% | -20.0% |
| Q4 2021 | $8,000 | -11.1% | 1,000 | 0.0% | 0.01% | -28.6% |
| Q3 2021 | $9,000 | -25.0% | 1,000 | 0.0% | 0.01% | -22.2% |
| Q2 2021 | $12,000 | -7.7% | 1,000 | 0.0% | 0.01% | -10.0% |
| Q1 2021 | $13,000 | -18.8% | 1,000 | 0.0% | 0.01% | -28.6% |
| Q4 2020 | $16,000 | +77.8% | 1,000 | 0.0% | 0.01% | +75.0% |
| Q3 2020 | $9,000 | 0.0% | 1,000 | 0.0% | 0.01% | -20.0% |
| Q2 2020 | $9,000 | +28.6% | 1,000 | -12.5% | 0.01% | +25.0% |
| Q1 2020 | $7,000 | -12.5% | 1,143 | +14.3% | 0.01% | -11.1% |
| Q4 2019 | $8,000 | – | 1,000 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Golden State Equity Partners | 154,360 | $897,000 | 0.45% |
| Rhenman & Partners Asset Management AB | 761,429 | $4,424,000 | 0.44% |
| Lombard Odier Asset Management (Switzerland) SA | 860,702 | $5,001,000 | 0.39% |
| WASATCH ADVISORS LP | 10,576,997 | $61,452,000 | 0.30% |
| Rokos Capital Management LLP | 977,663 | $5,861,000 | 0.27% |
| KLK CAPITAL MANAGEMENT LLC | 44,323 | $258,000 | 0.26% |
| Long Focus Capital Management, LLC | 340,000 | $1,975,000 | 0.25% |
| Vanguard Capital Wealth Advisors | 33,380 | $193,000 | 0.14% |
| Fort Sheridan Advisors LLC | 73,978 | $430,000 | 0.13% |
| Delphia (USA) Inc. | 20,983 | $122,000 | 0.09% |